The therapeutic intervention based on blocking the CD147 function with mAb could be promising, but although significant clinical progress has been made in the development of CD147-directed monoclonal antibodies for the treatment of different types of neoplasms, including hepatocellular carcinoma (HCC) [138,139], cervical cancer [140], lung cancer [141], and other solid tumors [16], few studies have explored the application of anti-CD147 antibodies in the field of hematological malignancies. This evidence concerns the gene BSG and cervical carcinoma.